Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23140063 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1HPGDTSHRALOX15 | |
| SCHEMBL13196346 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TSHRGAA | |
| SCHEMBL15482649 | 0.77 | TET2 (0.48) | SMN1; SMN2ALDH1A1HPGDTSHRALOX15 | |
| SCHEMBL8086112 | 0.76 | CA12 (0.38) | SMN1; SMN2ALDH1A1HPGDTSHRALOX15 | |
| SCHEMBL13196119 | 0.76 | RECQL (0.35) | TSHRALOX15GAA | |
| SCHEMBL232926 | 0.76 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1HPGDTSHRNPC1 | |
| SCHEMBL19295847 | 0.76 | HSD17B10 (0.34) | — | |
| SCHEMBL24599179 | 0.75 | TGM2 (0.37) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL8240200 | 0.75 | KDM4E (0.40) | ALDH1A1TSHR | |
| SCHEMBL20058252 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1HPGDTSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029791-B2 | Therapeutic conjugates | TOTUS MEDICINES INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029791-B2 | Therapeutic conjugates | TOTUS MEDICINES INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220387603-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220211855-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029791-B2 | Therapeutic conjugates | CD47, CD44, EPCAM | SMN1; SMN2 620/4885ALDH1A1 1307/4885HPGD 4136/4885 |
| US-20220387603-A1 | THERAPEUTIC CONJUGATES | CD47, CD44, EPCAM | SMN1; SMN2 620/4885ALDH1A1 1307/4885HPGD 4136/4885 |
| US-20220211855-A1 | THERAPEUTIC CONJUGATES | CD47, CD44, EPCAM | SMN1; SMN2 620/4885ALDH1A1 1307/4885HPGD 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.